keyword
MENU ▼
Read by QxMD icon Read
search

Prostate cancer survival

keyword
https://www.readbyqxmd.com/read/28318726/low-risk-prostate-cancer-identification-management-and-outcomes
#1
REVIEW
Marco Moschini, Peter R Carroll, Scott E Eggener, Jonathan I Epstein, Markus Graefen, Rodolfo Montironi, Christopher Parker
CONTEXT: The incidence of low-risk prostate cancer (PCa) has increased as a consequence of prostate-specific antigen testing. OBJECTIVE: In this collaborative review article, we examine recent literature regarding low-risk PCa and the available prognostic and therapeutic options. EVIDENCE ACQUISITION: We performed a literature review of the Medline, Embase, and Web of Science databases. The search strategy included the terms: prostate cancer, low risk, active surveillance, focal therapy, radical prostatectomy, watchful waiting, biomarker, magnetic resonance imaging, alone or in combination...
March 15, 2017: European Urology
https://www.readbyqxmd.com/read/28317581/radical-prostatectomy-in-denmark-survival-analysis-and-temporal-trends-in-clinicopathological-parameters-with-up-to-20-years-of-follow-up
#2
Mikael Heering, Kasper Drimer Berg, Klaus Brasso, Peter Iversen, Martin Andreas Røder
OBJECTIVES: To describe mortality, cause of death, and temporal trends in clinicopathological parameters with up to 20 years of follow-up in a nationwide cohort of prostate cancer (PCa) patients who underwent radical prostatectomy (RP). MATERIALS AND METHODS: A total of 6857 patients with PCa treated with RP at six different hospitals in Denmark between 1995 and 2011. Data were extracted from the nationwide DaPCa database. Histopathology reports from the RP specimens were manually reviewed...
March 2017: Surgical Oncology
https://www.readbyqxmd.com/read/28314971/-when-is-surgical-treatment-indicated-in-metastatic-prostate-cancer-and-what-is-the-scientific-rationale
#3
A Kretschmer, A Herlemann, C G Stief, C Gratzke
BACKGROUND: Recent improvements in imaging diagnostics has led to a rising incidence of oligometastatic prostate cancer and, most notably, an increasing incidence of nodal-only biochemical recurrences. In this clinical setting, systemic therapy is still the treatment of choice. However, there is increasing evidence for surgical approaches in this challenging clinical setting. AIM OF THE STUDY: In this comprehensive review article, current evidence regarding surgical approaches of primary nodal metastases, nodal-only biochemical recurrence following radical prostatectomy, and osseous metastatic prostate cancer will be discussed...
March 17, 2017: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/28314611/clinical-outcomes-from-androgen-signaling-directed-therapy-after-treatment-with-abiraterone-acetate-and-prednisone-in-patients-with-metastatic-castration-resistant-prostate-cancer-post-hoc-analysis-of-cou-aa-302
#4
Matthew R Smith, Fred Saad, Dana E Rathkopf, Peter F A Mulders, Johann S de Bono, Eric J Small, Neal D Shore, Karim Fizazi, Thian Kheoh, Jinhui Li, Peter De Porre, Mary B Todd, Margaret K Yu, Charles J Ryan
In the COU-AA-302 trial, abiraterone acetate plus prednisone significantly increased overall survival for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC). Limited information exists regarding response to subsequent androgen signaling-directed therapies following abiraterone acetate plus prednisone in patients with mCRPC. We investigated clinical outcomes associated with subsequent abiraterone acetate plus prednisone (55 patients) and enzalutamide (33 patients) in a post hoc analysis of COU-AA-302...
March 14, 2017: European Urology
https://www.readbyqxmd.com/read/28314320/the-clinical-efficacy-of-enzalutamide-in-metastatic-prostate-cancer-prospective-single-center-study
#5
Giuseppe Cicero, Rossella DE Luca, Patrizia Dorangricchia, Francesco Dieli
BACKGROUND/AIM: To evaluate the effectiveness of enzalutamide in Italian patients with hormone-refractory metastatic castration-resistant prostate cancer, progressing after chemotherapy with docetaxel plus prednisone. PATIENTS AND METHODS: A total of 60 patients were enrolled. Reduction in serum prostate-specific antigen (PSA) was assessed as the primary endpoint, while reduction in pain, safety, progression-free survival and overall survival represented secondary endpoints...
March 2017: Anticancer Research
https://www.readbyqxmd.com/read/28314292/-68-ga-psma-ligand-pet-ct-based-radiotherapy-for-lymph-node-relapse-of-prostate-cancer-after-primary-therapy-delays-initiation-of-systemic-therapy
#6
Christoph Henkenberens, Christoph A VON Klot, Tobias L Ross, Frank M Bengel, Hans-Jürgen Wester, Hüper Katja, Hans Christiansen, Thorsten Derlin
AIM: To evaluate (68)Ga-PSMA ligand positron-emission tomography-computed tomography (PET/CT)-based radiotherapy for lymph node metastases of prostate cancer after primary therapy. PATIENTS AND METHODS: Twenty-three patients received radiotherapy for PSMA ligand-positive lymph node metastases. RESULTS: The median follow-up time was 12.4 (range=6.0-28.5) months. The median pre-treatment prostate-specific antigen (PSA) decreased from 2.75 (range=0...
March 2017: Anticancer Research
https://www.readbyqxmd.com/read/28301631/androgen-receptor-function-and-androgen-receptor-targeted-therapies-in-breast-cancer-a-review
#7
Miho Kono, Takeo Fujii, Bora Lim, Meghan Sri Karuturi, Debasish Tripathy, Naoto T Ueno
Importance: The androgen receptor (AR) pathway is emerging as a potential therapeutic target in breast cancer. To date, AR-targeted drugs have been approved only for treatment of prostate cancer; however, AR-targeted treatment for breast cancer is an area of active investigation. Through review of preclinical studies, retrospective clinical studies, and clinical trials, we examined the biology of AR and AR-related pathways, the potential for AR-targeted therapies in breast cancer, and potential biomarkers for AR-targeted treatments...
March 16, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28300578/cellular-interactions-of-the-phosphorylated-form-of-akt-in-prostate-cancer
#8
Kai H Hammerich, Anna Frolov, Rile Li, Michael Ittmann, Gustavo E Ayala
Phospho-Akt (P-Akt1) promotes proliferation and increased survival in vitro and plays an important role in prostate cancer (PCa) progression as well as the prediction of the probability of recurrence. In this study, the goal was to demonstrate the involvement and impact of P-Akt1 on cellular interactions, biomechanisms and pathways in PCa. Tissue microarrays from 640 PCa patients were immunostained with various antibodies. Ki67 was used to measure proliferation index and Tunnel for apoptotic index. Increased expression of P-Akt1 was associated with an increased proliferation, but inversely correlated with apoptotic index...
March 11, 2017: Human Pathology
https://www.readbyqxmd.com/read/28300564/contrasting-roles-of-the-abcg2-q141k-variant-in-prostate-cancer
#9
Kathryn M Sobek, Jessica L Cummings, Dean J Bacich, Denise S O'Keefe
ABCG2 is a membrane transport protein that effluxes growth-promoting molecules, such as folates and dihydrotestosterone, as well as chemotherapeutic agents. Therefore it is important to determine how variants of ABCG2 affect the transporter function in order to determine whether modified treatment regimens may be necessary for patients harboring ABCG2 variants. Previous studies have demonstrated an association between the ABCG2 Q141K variant and overall survival after a prostate cancer diagnosis. We report here that in patients with recurrent prostate cancer, those who carry the ABCG2 Q141K variant had a significantly shorter time to PSA recurrence post-prostatectomy than patients homozygous for wild-type ABCG2 (P=0...
March 11, 2017: Experimental Cell Research
https://www.readbyqxmd.com/read/28300506/adding-celecoxib-with-or-without-zoledronic-acid-for-hormone-na%C3%A3-ve-prostate-cancer-long-term-survival-results-from-an-adaptive-multiarm-multistage-platform-randomized-controlled-trial
#10
Malcolm D Mason, Noel W Clarke, Nicholas D James, David P Dearnaley, Melissa R Spears, Alastair W S Ritchie, Gerhardt Attard, William Cross, Rob J Jones, Christopher C Parker, J Martin Russell, George N Thalmann, Francesca Schiavone, Estelle Cassoly, David Matheson, Robin Millman, Cyrill A Rentsch, Jim Barber, Clare Gilson, Azman Ibrahim, John Logue, Anna Lydon, Ashok D Nikapota, Joe M O'Sullivan, Emilio Porfiri, Andrew Protheroe, Narayanan Nair Srihari, David Tsang, John Wagstaff, Jan Wallace, Catherine Walmsley, Mahesh K B Parmar, Matthew R Sydes
Purpose Systemic Therapy for Advanced or Metastatic Prostate Cancer: Evaluation of Drug Efficacy is a randomized controlled trial using a multiarm, multistage, platform design. It recruits men with high-risk, locally advanced or metastatic prostate cancer who were initiating long-term hormone therapy. We report survival data for two celecoxib (Cel)-containing comparisons, which stopped accrual early at interim analysis on the basis of failure-free survival. Patients and Methods Standard of care (SOC) was hormone therapy continuously (metastatic) or for ≥ 2 years (nonmetastatic); prostate (± pelvic node) radiotherapy was encouraged for men without metastases...
March 13, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28299340/long-term-oncological-outcomes-for-young-men-undergoing-radical-prostatectomy-for-localized-prostate-cancer
#11
Daimantas Milonas, Zilvinas Venclovas, Inga Gudinaviciene, Kristina Zviniene, Aivaras Jonas Matjosaitis
Aim. The aim of this study was to describe PCa characteristics and long-term outcomes in young men aged ≤55 years after radical prostatectomy (RP) and to compare them with older men cohort. Methods. Among 2,200 patients who underwent RP for clinically localized PCa at our centre between 2001 and 2015, 277 (10.3%) men aged ≤55 years were identified. All preoperative and pathological parameters were compared between groups. Biochemical progression free survival (BPFS) and disease progression free survival (DPFS) were assessed at 5 and 10 years...
2017: BioMed Research International
https://www.readbyqxmd.com/read/28297567/developing-a-novel-two-dimensional-culture-system-to-enrich-human-prostate-luminal-progenitors-that-can-function-as-a-cell-of-origin-for-prostate-cancer
#12
Dingxiao Zhang, Kevin Lin, Yue Lu, Kiera Rycaj, Yi Zhong, Hsueh-Ping Chao, Tammy Calhoun-Davis, Jianjun Shen, Dean G Tang
Elucidating the cell of origin of cancer has great significance in stratifying patients into appropriate treatment groups and for developing novel targeted therapies. Early studies demonstrate that only stem-like basal cells in the normal human prostate (NHP) can function as the cell of origin for prostate cancer (PCa). Here, we show that the organoids derived from bulk NHP luminal cells can also be tumorigenically transformed. We further show that the WIT medium, which is used to culture human mammary epithelial progenitor cells, when combined with the ROCK inhibitor, can readily propagate a population of progenitor-like cells from the primary NHP luminal cell isolates...
March 2017: Stem Cells Translational Medicine
https://www.readbyqxmd.com/read/28296582/randomized-trial-of-a-hypofractionated-radiation-regimen-for-the-treatment-of-localized-prostate-cancer
#13
Charles N Catton, Himu Lukka, Chu-Shu Gu, Jarad M Martin, Stéphane Supiot, Peter W M Chung, Glenn S Bauman, Jean-Paul Bahary, Shahida Ahmed, Patrick Cheung, Keen Hun Tai, Jackson S Wu, Matthew B Parliament, Theodoros Tsakiridis, Tom B Corbett, Colin Tang, Ian S Dayes, Padraig Warde, Tim K Craig, Jim A Julian, Mark N Levine
Purpose Men with localized prostate cancer often are treated with external radiotherapy (RT) over 8 to 9 weeks. Hypofractionated RT is given over a shorter time with larger doses per treatment than standard RT. We hypothesized that hypofractionation versus conventional fractionation is similar in efficacy without increased toxicity. Patients and Methods We conducted a multicenter randomized noninferiority trial in intermediate-risk prostate cancer (T1 to 2a, Gleason score ≤ 6, and prostate-specific antigen [PSA] 10...
March 15, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28295408/circulating-tumor-cells-as-a-marker-for-progression-free-survival-in-metastatic-castration-na%C3%A3-ve-prostate-cancer
#14
Andreas Josefsson, Anna Linder, Despina Flondell Site, Giacomo Canesin, Anna Stiehm, Aseem Anand, Anders Bjartell, Jan-Erik Damber, Karin Welén
BACKGROUND: Analysis of circulating tumor cells (CTC) is a promising prognostic marker in castration-resistant prostate cancer (CRPC). The aim of this study was to investigate CTC detection and phenotyping as prognostic biomarkers for response to primary androgen deprivation therapy (ADT) of metastatic prostate cancer (PC). METHODS: PC patients presenting with a prostate specific antigen (PSA) >80 ng/ml and/or metastatic disease, intended for ADT were enrolled in the study...
March 10, 2017: Prostate
https://www.readbyqxmd.com/read/28292957/psma-redirects-cell-survival-signaling-from-the-mapk-to-the-pi3k-akt-pathways-to-promote-the-progression-of-prostate-cancer
#15
Leslie Ann Caromile, Kristina Dortche, M Mamunur Rahman, Christina L Grant, Christopher Stoddard, Fernando A Ferrer, Linda H Shapiro
Increased abundance of the prostate-specific membrane antigen (PSMA) on prostate epithelium is a hallmark of advanced metastatic prostate cancer (PCa) and correlates negatively with prognosis. However, direct evidence that PSMA functionally contributes to PCa progression remains elusive. We generated mice bearing PSMA-positive or PSMA-negative PCa by crossing PSMA-deficient mice with transgenic PCa (TRAMP) models, enabling direct assessment of PCa incidence and progression in the presence or absence of PSMA...
March 14, 2017: Science Signaling
https://www.readbyqxmd.com/read/28292923/aspirin-use-reduces-the-risk-of-aggressive-prostate-cancer-and-disease-recurrence-in-african-american-men
#16
Cheryl J Smith, Tiffany H Dorsey, Wei Tang, Symone V Jordan, Christopher A Loffredo, Stefan Ambs
BACKGROUND: Men of African descent experience a disproportionately high prostate cancer mortality. Intratumoral inflammation was found to be associated with aggressive prostate cancer. We and others have shown that prostate tumors in African-American (AA) patients harbor a distinct immune and inflammation signature when compared with European-American (EA) patients. These observations suggest that inflammation could be a driver of aggressive disease in men of African descent, leading to the hypothesis that an anti-inflammatory drug like aspirin could prevent disease progression...
March 14, 2017: Cancer Epidemiology, Biomarkers & Prevention
https://www.readbyqxmd.com/read/28292438/maoa-dependent-activation-of-shh-il6-rankl-signaling-network-promotes-prostate-cancer-metastasis-by-engaging-tumor-stromal-cell-interactions
#17
Jason Boyang Wu, Lijuan Yin, Changhong Shi, Qinlong Li, Peng Duan, Jen-Ming Huang, Chunyan Liu, Fubo Wang, Michael Lewis, Yang Wang, Tzu-Ping Lin, Chin-Chen Pan, Edwin M Posadas, Haiyen E Zhau, Leland W K Chung
Metastasis is a predominant cause of death for prostate cancer (PCa) patients; however, the underlying mechanisms are poorly understood. We report that monoamine oxidase A (MAOA) is a clinically and functionally important mediator of PCa bone and visceral metastases, activating paracrine Shh signaling in tumor-stromal interactions. MAOA provides tumor cell growth advantages in the bone microenvironment by stimulating interleukin-6 (IL6) release from osteoblasts, and triggers skeletal colonization by activating osteoclastogenesis through osteoblast production of RANKL and IL6...
March 13, 2017: Cancer Cell
https://www.readbyqxmd.com/read/28291739/a-radiobiological-model-of-metastatic-burden-reduction-for-molecular-radiotherapy-application-to-patients-with-bone-metastases
#18
Ana M Denis-Bacelar, Sarah J Chittenden, Iain Murray, Antigoni Divoli, V Ralph McCready, David P Dearnaley, Joe M O'Sullivan, Bernadette Johnson, Glenn D Flux
Skeletal tumour burden is a biomarker of prognosis and survival in cancer patients. This study proposes a novel method based on the linear quadratic model to predict the reduction in metastatic tumour burden as a function of the absorbed doses delivered from molecular radiotherapy treatments. The range of absorbed doses necessary to eradicate all the bone lesions and to reduce the metastatic burden was investigated in a cohort of 22 patients with bone metastases from castration-resistant prostate cancer. A metastatic burden reduction curve was generated for each patient, which predicts the reduction in metastatic burden as a function of the patient mean absorbed dose, defined as the mean of all the lesion absorbed doses in any given patient...
April 7, 2017: Physics in Medicine and Biology
https://www.readbyqxmd.com/read/28291248/a-curated-collection-of-tissue-microarray-images-and-clinical-outcome-data-of-prostate-cancer-patients
#19
Qing Zhong, Tiannan Guo, Markus Rechsteiner, Jan H Rüschoff, Niels Rupp, Christian Fankhauser, Karim Saba, Ashkan Mortezavi, Cédric Poyet, Thomas Hermanns, Yi Zhu, Holger Moch, Ruedi Aebersold, Peter J Wild
Microscopy image data of human cancers provide detailed phenotypes of spatially and morphologically intact tissues at single-cell resolution, thus complementing large-scale molecular analyses, e.g., next generation sequencing or proteomic profiling. Here we describe a high-resolution tissue microarray (TMA) image dataset from a cohort of 71 prostate tissue samples, which was hybridized with bright-field dual colour chromogenic and silver in situ hybridization probes for the tumour suppressor gene PTEN. These tissue samples were digitized and supplemented with expert annotations, clinical information, statistical models of PTEN genetic status, and computer source codes...
March 14, 2017: Scientific Data
https://www.readbyqxmd.com/read/28289065/gleason-grade-grouping-of-prostate-cancer-is-of-prognostic-value-in-asian-men
#20
Joe Yeong, Rehena Sultana, Jonathan Teo, Hong Hong Huang, John Yuen, Puay Hoon Tan, Li Yan Khor
AIM: The International Society of Urological Pathology made recommendations for the use of Grade Groups (GG) originally described by Epstein and colleagues over Gleason score (GS) alone in 2014, which was subsequently adopted by the WHO classification in 2016. The majority of studies validating this revision have been in Caucasian populations. We therefore asked whether the new GG system was retrospectively associated with biochemical disease-free survival in a mixed-ethnicity cohort of Asian men...
March 13, 2017: Journal of Clinical Pathology
keyword
keyword
8536
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"